Bruce Bode

Summary

Publications

  1. ncbi request reprint Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
    Diabetes Care 25:439-44. 2002
  2. ncbi request reprint Patient perception and use of an insulin injector/glucose monitor combined device
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Road NW, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Educ 30:301-9. 2004
  3. doi request reprint Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30309, USA
    Hosp Pract (1995) 37:7-21. 2009
  4. ncbi request reprint Liraglutide: a review of the first once-daily GLP-1 receptor agonist
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Rd, Ste 2080, Atlanta, GA 30309, USA
    Am J Manag Care 17:S59-70. 2011
  5. ncbi request reprint The suboptimal roadmap to the intensive therapy target
    Paul Davidson
    Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
    Diabetes Technol Ther 6:17-9. 2004
  6. ncbi request reprint Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, Georgia, USA
    Diabetes Technol Ther 6:105-13. 2004
  7. doi request reprint Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30318, USA
    Hosp Pract (1995) 41:72-84. 2013
  8. doi request reprint An overview of the pharmacokinetics, efficacy and safety of liraglutide
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Res Clin Pract 97:27-42. 2012
  9. ncbi request reprint Evaluation of a continuous glucose monitoring system for home-use conditions
    Bruce Bode
    Atlanta Diabetes Associates, USA
    Manag Care 17:40-5. 2008
  10. ncbi request reprint Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs
    Philip Raskin
    Department of Internal Medicine, Southwestern Medical Center at Dallas, Dallas, TX 75390 8858, USA
    Diabetes Care 28:260-5. 2005

Detail Information

Publications13

  1. ncbi request reprint Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
    Diabetes Care 25:439-44. 2002
    ..To compare the safety and efficacy of insulin aspart (IAsp), buffered regular insulin (BR), and insulin lispro administered by continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes...
  2. ncbi request reprint Patient perception and use of an insulin injector/glucose monitor combined device
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Road NW, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Educ 30:301-9. 2004
    ..This clinical trial assessed patient preference, satisfaction, and use of an insulin injector/glucose monitor combination device versus syringes and a separate glucose monitor...
  3. doi request reprint Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30309, USA
    Hosp Pract (1995) 37:7-21. 2009
    ..This review examines the challenges to achieving glycemic control in the hospital setting and summarizes clinical data on the efficacy and safety of incretin-based therapies in their use in the hospital and after discharge...
  4. ncbi request reprint Liraglutide: a review of the first once-daily GLP-1 receptor agonist
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Rd, Ste 2080, Atlanta, GA 30309, USA
    Am J Manag Care 17:S59-70. 2011
    ..The guidelines prefer GLP-1 agonists over DPP-4 inhibitors because of their actions that promote weight loss and their somewhat greater effectiveness in reducing postprandial glucose excursions...
  5. ncbi request reprint The suboptimal roadmap to the intensive therapy target
    Paul Davidson
    Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
    Diabetes Technol Ther 6:17-9. 2004
  6. ncbi request reprint Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, Georgia, USA
    Diabetes Technol Ther 6:105-13. 2004
    ....
  7. doi request reprint Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30318, USA
    Hosp Pract (1995) 41:72-84. 2013
    ....
  8. doi request reprint An overview of the pharmacokinetics, efficacy and safety of liraglutide
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Res Clin Pract 97:27-42. 2012
    ..The aim of this review is to assess the pharmacokinetics, efficacy and safety of the phase 3 data...
  9. ncbi request reprint Evaluation of a continuous glucose monitoring system for home-use conditions
    Bruce Bode
    Atlanta Diabetes Associates, USA
    Manag Care 17:40-5. 2008
    ..To evaluate the safety and effectiveness of the FreeStyle Navigator Continuous Glucose Monitoring System when used by adult patients with type 1 or 2 diabetes requiring insulin in the home environment...
  10. ncbi request reprint Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs
    Philip Raskin
    Department of Internal Medicine, Southwestern Medical Center at Dallas, Dallas, TX 75390 8858, USA
    Diabetes Care 28:260-5. 2005
    ..Safety and efficacy of biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) were compared with once-daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs (OADs)...
  11. ncbi request reprint Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial
    Robert Tanenberg
    Brody School of Medicine, Greenville, NC, USA
    Mayo Clin Proc 79:1521-6. 2004
    ....
  12. ncbi request reprint Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes
    Berrin Ergun-Longmire
    Division of Pediatric Endocrinology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
    Ann N Y Acad Sci 1029:260-77. 2004
    ..If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late-onset immune-mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion...